Institut Catala De Retina S.L.

Barcelona 19 trials 7 recruiting

19 Registered trials

7 Currently recruiting

Organisation

Institut Catala De Retina S.L.

Location

Barcelona, Spain

Identifier

ORG-100044100

Address

Calle De La Pau Alcover 67, 08017, Spain

Departments

2115: Oftalmología
724007: Oftalmología
Clinical Trial Unit
NA
Ophtalmology
Ophthalmology
Ophthalmology service
Retinal Department
Servicio de Oftalmologia

Clinical trials at this site (19)

Search interface

A clinical trial to assess the efficacy and safety of ADX-308, a new type of treatment for Geographic Atrophy (GA), an advanced stage of eye… Pending

2025-521779-30-00 Geographic atrophy secondary to age-related macular deg 4
Study to Assess the Ability of ONL1204 to Slow the Progression of Atrophic Age-related Macular Degeneration Recruiting

2024-513174-22-00 Atrophic Age-related Macular Degeneration (AMD) 4 2026-04-14
A Phase 3, Randomized, Double-Masked, Active-Controlled Trial of a Single Intravitreal Injection of 4D-150 in Adults with Macular Neovascula… Recruiting

2025-521349-25-00 Macular neovascularization secondary to age-related mac 5 2025-12-09
A phase IV, multicentre, open-label, single-arm study to investigate the efficacy, safety and durability of faricimab (RO6867461) in caucasi… Recruiting

2024-515640-22-00 polypoidal choroidal vasculopathy 6 2025-08-06
A study Investigating Subcutaneously Administered Pozelimab in Combination with Cemdisiran or Cemdisiran Alone in Adult Participants with Ge… Recruiting

2023-509547-27-00 Geographic Atrophy Secondary to Age-Related Macular Deg 5 2025-05-22
Long-term Extension Study for Participants with Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD) in JNJ-81201887 … Recruiting

2022-500747-21-00 Geographic Atrophy 4 2025-02-27
A multicentric, randomized, double-blind, placebo-controlled trial to evaluate the efficacy of COLIRIOBCN070660 administered topically in pa… Recruiting

2023-505791-30-01 Diabetic Retinopathy 10 2024-04-17
A study to assess efficacy of citicoline on visual field preservation in patients with glaucoma Recruiting

2022-502273-42-00 Glaucoma 5 2023-11-08
A randomized study to evaluate the Efficacy and Safety of Intravitreal EYE103 Compared to Anti-VEGF Ended

2025-520809-12-00 Diabetic Macular Edema 10 2025-10-16
A Safety, and Tolerability Study of VRDN-003 in Participants with Thyroid Eye Disease (TED) Ended

2024-519417-57-00 Thyroid eye disease 5 2025-06-25
A Study Investigating the Efficacy and Safety of Intravitreal Injections of ANX007 in Participants with Dry Age-Related Macular Degeneration… Ended

2024-515022-88-00 Dry Age-Related Macular Degeneration (AMD) with geograp 5 2025-03-03
A randomized study to evaluate the Efficacy and Safety of Intravitreal EYE103 Compared to Anti-VEGF (in patients with Diabetic Macular Edema… Ended

2024-510944-30-00 Diabetic Macular Edema 10 2024-11-22
A study of efgartigimod PH20 SC given by prefilled syringe in adults with thyroid eye disease Ended

2023-509198-22-00 Thyroid Eye Disease (TED) 5 2024-10-21
A study to evaluate Intravitreal JNJ-81201887(AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary… Ended

2022-500746-16-00 Geographic Atrophy 4 2023-08-11
A Phase 3 Study to Investigate the Safety and Efficacy of Ripasudil (K-321) in Subjects with Fuchs Dystrophy Ended

2022-502643-35-00 Fuchs Endothelial Corneal Dystrophy 5 2023-08-09
A Study to Investigate the Safety and Effectiveness of Ripasudil (K-321) Eye Drops After Descemetorhexis in Subjects with Fuchs Endothelial … Ended

2024-511752-40-00 Fuchs Endothelial Corneal Dystrophy 5 2023-05-05
An Open-Label Extension Study for Patients who Previously Completed Study ISEE2008 (GATHER2) Ended

2024-515185-13-00 geographic atrophy 5 2022-12-21
A Study of Danicopan in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration Ended

2023-508571-37-00 Geographic atrophy (GA) secondary to Age-related Macula 4 2022-04-29
A clinical study of OPT-302 with aflibercept compared to aflibercept alone in patients with neovascular age-related macular degeneration Ended

2024-512880-30-00 Neovascular Age-related Macular Degeneration (wet AMD) 5 2021-08-27